Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease

[at noodls] – Phase 2 AT2220-ERT Co-Administration and Preclinical AT2220-ERT Co-Formulation Studies Presented at LDN WORLD Symposium Next-Generation ERT Advancing in Preclinical Studies Conference Call on February … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard

See who Amicus is hiring next, click here to view